Abbott Laboratories (NYSE:ABT) Getting Ready to Announce Fiscal Q4 Results – ABT, PFE, GSK, MRK

Abbott Laboratories (NYSE:ABT) will announce its financial results for most recent quarter on Wednesday, January 23, 2013.

The median forecast of analysts is for net income of $1.50 a share, a lift of 3.4% from the Abbott Park, Illinois based company’s actual earnings for the similar period previous year.

The median forecasts have moved down from $1.51 during the previous 3 months. Analysts are forecasting profit to boost by 8.4% evaluated against previous year’s $5.06.

The drug giant has surpassed forecasts the previous four quarters and is coming off a three months period where it topped estimates by 2 cents, announcing a profit of $1.30 a share against a median forecast of net income of $1.28 a share.

Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Pfizer Inc. (NYSE:PFE) fell -1.08% to settle at $26.54, GlaxoSmithKline plc (ADR) (NYSE:GSK) moved down -0.18% to end at $43.94 while Merck & Co., Inc. (NYSE:MRK) jumped +0.54% to finish at $42.98 on Friday.

Abbott Laboratories (NYSE:ABT) last session’s volume of 14.99 million shares was surprisingly higher than its average volume of 10.11 million shares. The stock after opening at $32.80 hit high price of $32.87 and then closed at $32.74 by scoring -0.12%.

The liquidity measure in recent quarter results of the company was recorded 1.67 as current ratio and on the other side the debt to equity ratio was 0.60 and long-term debt to equity ratio remained at 0.45. The Company had total cash of $11.50 billion at hand and a book value per share as $17.09 in the most recent quarter.

The stock’s price volatility was 1.18% for a week and 1.43% for a month as well as price volatility’s Average True Range for 14 days was 0.49 and its beta remained at 0.33.

ABT generated revenue of $39.41 billion in the previous twelve months and earned $6.53 billion. The Company showed a positive 16.56% in the net profit margin as well as in its operating margin which remained at 19.67%. Company’s annual sales growth for the past five years was 11.57%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , . Bookmark the permalink.